96results about How to "Lower level" patented technology

A right-hand circularly-polarized patch antenna comprising a ground plane and a patch connected to each other with one or more wires for which the wire shape and location of the end points are selected such that they do not cause an antenna mismatch, and the electrical current carried in the wires produces an extra electromagnetic field subtracted from the patch field in the nadir direction.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

This invention discloses an anti-inflammatory peptide derived from pearl oysters and its applications, relating to the field of bioactive peptide technology. The amino acid sequence of this anti-inflammatory peptide is TAMY. The anti-inflammatory peptide derived from pearl oysters provided by this invention can regulate the release of cellular inflammatory mediators, reduce the levels of NO and pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β), and simultaneously promote the secretion of anti-inflammatory cytokines (such as IL-10), exhibiting excellent anti-inflammatory activity and suitable for use in functional foods, cosmetics, or pharmaceutical ingredients.

This invention relates to the field of organoid disease models, and discloses a method for constructing a human brain organoid model of early-onset Alzheimer's disease (AD) and its applications. This invention introduces [a specific technology] into human embryonic stem cell lines through single-base editing and lead editing techniques. PSEN1 ΔE9、 PSEN1 M146V and APP Human embryonic stem cell lines carrying four familial pathogenic gene mutations (K670N and M671L) were constructed and induced to differentiate into Alzheimer's disease (AD) brain organoids. The AD brain organoid model established by this invention exhibited tau phosphorylation pathological phenotypes as early as 20 days and Aβ-related phenotypes as early as 40 days, with increased total Aβ, decreased Aβ42 / Aβ40 ratio, and simultaneous aggravation of Aβ-Tau pathology. This represents a complex neurodegenerative pathological model where multiple mutations synergistically regulate Aβ production and tau phosphorylation, which is highly valuable for understanding and studying early-onset familial AD. This invention provides a human brain organoid model for in vitro AD studies and offers a tool for studying the pathological mechanisms of AD and screening drugs.

The invention discloses a construction method of a conditional knock-down dynactin animal model of astrocytes and an application of the animal model of the conditional knock-down dynactin animal model of the astrocytes. According to the method, a Dctn1LoxP gene knock-in mouse is hybridized with an Aldh1l1-Cre / ERT2 transgenic mouse, a target genotype mouse is obtained through three rounds of breeding, 100mg / kg Tamoxifen is continuously injected into the intraperitoneal cavity of the 2-month-old mouse for 5 days, and specific knock-down of dynactin in brain and spinal astrocytes is realized, including knockout of p150Glue and reduction of DCTN4, p50 and Arp1alpha protein levels. The model has the advantages of being high in specificity, permanent in intervention aging and capable of covering multiple life stages, the defects of a traditional model are overcome, the model can be used for researching the influence of dynactin on astrocyte neurobiological functions, a reliable tool is provided for screening related targets of nervous system diseases, and the model has important application value.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The invention provides a manufacturing method of fried chicken with buckwheat. The manufacturing method comprises the following steps: a first stage of burying chicken which is cut into a certain size and is processed in impurity-removed sauce to remove foreign flavor; a second stage of blanching the chicken from which the foreign flavor is removed in boiling water for 1-3 times; a third stage of removing moisture from the scalded chicken; a fourth stage of applying a fried coat to the chicken from which the moisture is removed; a fifth stage of frying the fried chicken with oil at a temperature of 170 DEG C for 7 minutes; in the sixth stage, the buckwheat mixed sauce is mixed on the fried chicken, the fried buckwheat is crushed by the buckwheat mixed sauce through a crushing machine, and 100 parts of the crushed buckwheat is added into the fried chicken; the sauce is prepared from the following raw materials in parts by weight: 100 parts of mixed water, 10-20 parts of syrup, 5-10 parts of tomato sauce, 10 parts of chili sauce, 10 parts of mixed seasoning, 3-5 parts of fragrant rice oil, 5 parts of jade-fold oil, 10 parts of tomato sauce, 2 parts of onions, 1 part of soy sauce, 2 parts of soy sauce, 1 part of curry, 0.5 part of L-sodium glutamate, 0.5 part of agricultural processed products, 0.5 part of fresh ginger and 0.3 part of red pepper extract pigment.

The invention provides composite haw jelly and a preparation method thereof. The composite haw jelly comprises the following raw materials in parts by weight: 90-100 parts of haw pulp, 1.8-2.0 parts of russule, 27-30 parts of white granulated sugar and 1.8-2.0 parts of composite gel. The prepared haw jelly has the advantages of being low in heat and sugar, high in nutrient content, good in health care effect and the like, and has a wide range of audiences.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

This invention discloses an engineered probiotic expressing D-lactate dehydrogenase, its construction method, and its applications, belonging to the field of biomedical technology. The engineered probiotic of this invention is constructed by exogenously introducing the D-lactate dehydrogenase encoding gene into *Escherichia coli* Nissle 1917. This invention utilizes synthetic biology techniques to construct a "living therapeutic factory" capable of in-situ clearing specific metabolites, realizing a paradigm shift from "inhibiting proteins" to "clearing metabolites" in treatment. Through lipid coating technology, oral delivery and intestinal targeted colonization of the engineered bacteria are achieved, improving the precision and efficiency of treatment. Based on the probiotic EcN, it exhibits high biosafety. The treatment process is oral administration, non-invasive, and avoids the systemic toxicity of traditional chemotherapy.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

The application discloses a bidirectional multi-level conversion circuit, comprising: a first resistor, a first end of which is connected with a communication link signal, and a second end of which is connected with a power supply voltage; a second resistor, a first end of which is connected with the communication link signal, and a second end of which is connected with the power supply voltage through a second switch device; a fifth resistor, a first end of which is connected with a control end of a third switch device, and a second end of which is connected between a seventh resistor and a first switch device; a sixth resistor, a first end of which is connected with the control end of the third switch device, and a second end of which is connected with the power supply voltage; the seventh resistor is connected with the ground through the first switch device; a control end of the first switch device is connected with the communication link signal through a third resistor; a control end of the second switch device is connected with the power supply voltage through the third switch device, and the control end of the second switch device is connected with the first switch device through the seventh resistor. The application has the advantages of better signal quality, lower low level, slower rising edge, higher communication rate, and low cost.

This application belongs to the field of medicinal chemistry and relates to fused imide derivatives of Formula I, their preparation methods, pharmaceutical compositions containing the compound, and their use in treating related diseases (e.g., cancer).

The present invention relates to a novel compound comprising an ester group and uses thereof and, more particularly, to a novel compound that exhibits excellent visualization ability in a tumor by using the difference in activity of esterase for each organ in the body, and to uses therefor for diagnosing or treating cancer. A novel compound of chemical Formulas 1 to 8 according to the present invention exhibits selectivity according to the difference in activity of esterase for each organ due to ester residue in a structure, and thus is extremely effective in visualizing pancreatic cancer, etc.

The present application relates to the technical field of zinc metal battery, in particular to a multifunctional composite gel electrolyte, its preparation method and application. The present application provides a composite gel electrolyte, which comprises a polymer gel matrix, a zinc salt and a ZnHA filler; wherein the ZnHA filler is a hydroxyapatite material doped with zinc ions. The electrolyte is prepared by polymer dissolution, zinc salt addition, ZnHA dispersion, three-dimensional printing forming, low-temperature gelation and zinc salt solution activation, and has good shear thinning characteristics, self-supporting property and printability. Further, a three-dimensional printed interdigital structure electrode is constructed, and the electrolyte is covered to form an ion transmission channel, and a flexible zinc metal battery is assembled; multiple monomers can be connected in series to increase the output voltage. The flexible battery has excellent ion transmission, cycle stability, flexibility and safety, and can be used in the fields of flexible electronics, wearable devices and intelligent sensing.

The invention discloses a pharmaceutical composition for improving glucose and lipid metabolism disorder by combining N-p-coumaroyl octoamine and rotundine and application of the pharmaceutical composition, and belongs to the field of biological medicine and metabolic disease treatment. In a db / db diabetic mouse model, it is found that NTPC (10 mg / kg) or ROT (10 mg / kg) single drugs can improve hyperglycemia and insulin resistance and reduce blood fat, and low-dosage combination (5 mg / kg of NTPC and 5 mg / kg of ROT) shows the most significant metabolism improvement effect which is obviously better than that of a single drug group. In an in-vitro fatty acid stimulation model, lipid accumulation in cells can be more remarkably reduced through combination of the two drugs, and fatty acid synthesis genes are inhibited.

This invention relates to the field of grain dryer technology, specifically to a grain dryer discharge mechanism with an anti-breakage structure. The mechanism includes a main body with a discharge chamber at its bottom, connected to a grain receiving hopper at the bottom; a frame unit located within the discharge chamber, comprising a first frame slidably connected to the inner wall of the discharge chamber, and a second frame slidably nested in the middle of the first frame; both the first and second frames have connecting grooves on their outer walls, with the two sets of grooves facing opposite directions; a partition plate fixed inside the discharge chamber above the frame unit, with several discharge ports extending through its top; and a drive unit located within the discharge chamber. This invention enables low-breakage discharge throughout the entire grain dryer process, single-drive multi-mode controllable discharge, and also helps to break up knots and prevent damage. The purely mechanical structure ensures stable operation and is suitable for drying various grains.

This invention relates to the field of traditional Chinese medicine technology, and more particularly to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of lung injury. The traditional Chinese medicine composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that this traditional Chinese medicine composition can significantly reduce the level of the inflammatory factor TNF-α, decrease the lung index, and alleviate pathological damage to lung tissue, and can be used for the prevention and treatment of lung injury.

This invention relates to a traditional Chinese medicine composition, specifically a traditional Chinese medicine composition for treating diabetic nephropathy, belonging to the fields of medicine and health products. The traditional Chinese medicine composition of this invention is made from components comprising the following raw materials: yam, salvia miltiorrhiza, rosehip, turtle shell, cornus officinalis, dioscorea hypoglauca, cuscuta chinensis, oyster shell, and American ginseng. Through rational formulation, this traditional Chinese medicine composition utilizes the principle of clearing heat and removing dampness, with the synergistic effect of multiple drugs, to significantly reduce fasting blood glucose, improve glucose metabolism, lower low-density lipoprotein cholesterol and triglycerides, and raise high-density lipoprotein cholesterol to regulate lipid metabolism, reduce weight, and has no significant damage to liver and kidney function, with minimal side effects.

The invention discloses bifidobacterium longum CCFM1509 with autophagy promoting and colon aging resisting functions and application of the bifidobacterium longum CCFM1509, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1509 provided by the invention can relieve colon tissue pathological damage caused by senescence, reduce the level of proinflammatory cytokines in colon tissues, reduce the oxidative stress level in the colon tissues, reduce the level of senescence-related senescence markers in the colon tissues and adjust the autophagy level in the colon tissues. Therefore, the bifidobacterium longum CCFM1509 disclosed by the invention can be widely applied to the field of medicines and is used for preparing pharmaceutical preparations for preventing or treating colon aging and related diseases; meanwhile, the bacillus subtilis can also be used for developing various functional fermented foods, health foods and formula foods for special medical purposes, provides a new microbial solution for promoting intestinal health and delaying colon senescence, and has important development value and wide market prospects.

The invention discloses an application of a Yinxiaonaotong soft capsule in preparation of a medicine for preventing and treating acute lung injury, and experimental research shows that the Yinxiaonaotong soft capsule can significantly improve lung histopathologic injury of an acute lung injury mouse model activated and induced by a complement bypass and relieve inflammatory cell infiltration. The mechanism of action is as follows: the Yindanaotong can effectively inhibit the expression of key inflammatory mediators (TNF-alpha, IL-6) and adhesion molecules (ICAM-1, P-selectin) in lung tissues and serum. Meanwhile, the medicine can down-regulate the mRNA transcriptional level of NF-kappa B p65, JNK, p38 MAPK and STAT3 signal channel related genes in lung tissues and inhibit phosphorylation activation of corresponding proteins. The results comprehensively show that the Yindan Xinnaotong compound intervenes in an inflammation signal channel through multiple targets, and plays roles in resisting inflammation and protecting lung tissues, so that the Yindan Xinnaotong compound can be used for preparing medicines for preventing and / or treating acute lung injury.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

This invention relates to the field of biomedical technology, and in particular to the application of triptolide or its pharmaceutically acceptable salts in the preparation of medicaments for treating ketoacidosis or its symptoms. This invention provides the application of triptolide or its pharmaceutically acceptable salts in the preparation of medicaments for treating ketoacidosis or its symptoms. Results from specific embodiments of this invention show that triptolide can significantly reduce serum β-hydroxybutyrate levels in mice induced by starvation; triptolide can significantly reduce HMGCS2 expression in mouse livers; dapagliflozin significantly promotes β-hydroxybutyrate levels, while triptolide significantly reduces serum β-hydroxybutyrate levels in mice treated with dapagliflozin. Therefore, triptolide can be used to treat or improve ketoacidosis or its symptoms. This invention provides a new technical solution for the treatment and improvement of ketoacidosis or its symptoms.

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

This invention relates to the field of biomedical technology, specifically to the application of the MSR1 gene in the regulation of necrosis and apoptosis of dendritic cells (DCs) in sepsis. This application reduces DC necrosis and apoptosis during sepsis by knocking out the MSR1 gene, providing a novel therapeutic target for sepsis.

The present application belongs to the field of nutritional composition and biological medicine technology, and particularly relates to a composition for protecting and preserving liver, a preparation method, application and product thereof. The composition of the present application is composed of extract of Silybum marianum, glucoraphanin and extract of Cynara scolymus. The composition of the present application can intervene the pathological process of liver injury from multiple dimensions such as antioxidation, anti-inflammation, regulation of lipid metabolism and repair of hepatocytes through synergistic effect of the three components, significantly reduces the levels of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, reduces the accumulation of liver fat, improves the antioxidant capacity of the body, effectively prevents or improves alcoholic, chemical, non-alcoholic fatty and autoimmune liver injury, delays the progression of liver fibrosis, and comprehensively maintains the structural integrity and functional stability of the liver.

The application provides a parabolic antenna. The parabolic antenna comprises a feed source assembly, a support rod and a parabolic reflector. The feed source assembly comprises a feed source cover and a PCB oscillator arranged in the feed source cover. The two ends of the support rod are connected to the focal point of the parabolic reflector and the feed source cover respectively. The feed source cover comprises a first sub-cover and a second sub-cover which are connected to each other. The first sub-cover is farther away from the support rod than the second sub-cover. In the direction towards the support rod, the first sub-cover is in a cylindrical shape with a diameter which is first tapered and then expanded. The second sub-cover is in a cylindrical shape or in a cylindrical shape with a diameter which is expanded by less than or equal to 5%. The shape of the connection between the first sub-cover and the second sub-cover changes abruptly. The parabolic antenna has a simple structure, a small number of parts, a low cost, high electrical performance and high environmental reliability.

The invention provides a plant-derived active polypeptide and application thereof in prevention or treatment of Parkinson's syndrome, and belongs to the technical field of polypeptide bioengineering. The amino acid sequence of the active polypeptide is MKGASSIMYALG, and the active polypeptide is prepared from Fuding white tea raw materials through a directional two-step enzymolysis process. According to the polypeptide, the damage of 6-OHDA induced BZ555 nematode dopaminergic neurons can be remarkably reduced, and the dyskinesia of Parkinson's syndrome model animals can be remarkably improved; meanwhile, the expression level of proinflammatory factors such as IL-1beta and IL-18 in serum of a model mouse can be lowered, the content of dopamine in a nigra area of brain tissue of the model mouse can be increased, and the activity of monoamine oxidase B can be reduced. The results show that the Fuding white tea-derived active polypeptide has exact prevention and treatment effects on Parkinson's syndrome, and has important development value and wide application prospects in the field of medicines.

This application relates to the biomedical field, specifically to a GalNAc delivery molecule and its applications. This application provides a GalNAc-oligonucleotide conjugate having the structure shown in Formula I or Formula II. The GalNAc-oligonucleotide conjugate and its drug provided in this application have high delivery efficiency, enabling the delivery of oligonucleotides to the liver to inhibit the expression of target genes, thereby reducing the expression level of target proteins in the liver and providing a new approach for treating liver-related diseases.